ReferenceID 5917
Oroxylin A inhibits the migration of hepatocellular carcinoma cells by inducing NAG-1 expression
Acta Pharmacol Sin
Hepatocellular carcinoma (HCC), the most prevalent liver cancer, is considered one of the most lethal malignancies with a dismal outcome mainly due to frequent intrahepatic and distant metastasis. In the present study, w
Relationship Network
Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.
Click a node to open it in a new tab
Ingredient: 1Reference: 1Links: 1
Arranging relationship network...
Record Fields
Scalar fields from the final reference record.
- Reference Id
- 5917
- Evidence Id
- 22507
- Core Evidence Id
- 22507
- Source Reference Id
- 5092
- Herb2 Reference Id
- HBREF005889
- Subject Paper Key
- HBIN038303_34117368
- Pubmed Id
- 34117368
- Doi
- 10.1038/s41401-021-00695-4
- Paper Title
- Oroxylin A inhibits the migration of hepatocellular carcinoma cells by inducing NAG-1 expression
- Paper Abstract
- Hepatocellular carcinoma (HCC), the most prevalent liver cancer, is considered one of the most lethal malignancies with a dismal outcome mainly due to frequent intrahepatic and distant metastasis. In the present study, we demonstrated that oroxylin A, a natural product extracted from Scutellaria radix, significantly inhibits transforming growth factor-beta1 (TGF-beta1)-induced epithelial-mesenchymal transition (EMT) and metastasis in HCC. Oroxylin A blocked the TGF-beta1/Smad signaling via upregulating the non-steroidal anti-inflammatory drug-activated gene-1 (NAG-1) expression. Oroxylin A promoted NAG-1 transcription by regulating the acetylation of CCAAT/enhancer binding protein beta (C/EBPbeta), a transcription factor that binds to the NAG-1 promoter. In terms of the underlying mechanism, oroxylin A may interact with histone deacetylase 1 (HDAC1) by forming hydrogen bonds with GLY149 residue and induce proteasome-mediated degradation of HDAC1 subsequently impairing HDAC1-mediated deacetylation of C/EBPbeta and promoting the expression of NAG-1. Taken together, our findings revealed a previously unknown tumor-suppressive mechanism of oroxylin A. Oroxylin A should be further investigated as a potential clinical candidate for inhibiting HCC metastasis.
- Journal
- Acta Pharmacol Sin
- Publish Year
- 2022
- Experiment Subject
- Experiment Type
- Cell Experiment
- Phenotype Related
- Malignancies; Liver Cancer; Intrahepatic And Distant Metastasis; Hepatocellular Carcinoma
- Paper Title Cn
- Paper Title En
- Oroxylin A inhibits the migration of hepatocellular carcinoma cells by inducing NAG-1 expression
- Bilingual Status
- semi_complete